Sales up at MSD while Keytruda hits survival target in late-stage trial
October 28, 2015Research and Development, Sales and Marketing MSD, Merck, financial results, keytruda, pembrolizumab
Worldwide sales at MSD were $10.1 billion in the third quarter of 2015, a 4% increase after accounting for the …
Otsuka, GW announce Sativex fails in Phase III cancer pain trials
October 28, 2015Research and Development, Sales and Marketing Cancer, GX Pharmaceuticals, Otsuka, Sativex, cancer pain, palliative care, phase III, phase III failure
Otsuka and GW Pharmaceuticals cannabis-based drug Sativex failed to show superiority over placebo in two Phase III trials.The studies were …
OPINION: ‘More work remains if biosimilars are to fulfil their potential’
October 27, 2015Manufacturing and Production, Research and Development, Sales and Marketing British Generic Manufacturers Association, NHS, bgma, biosimilars, generics, patent cliff, patents
Despite having a mature generics market which fulfils more than three-quarters of all prescriptions in the UK, and as a …
Pharma reaction to the Government’s AAR review
October 27, 2015Manufacturing and Production, Research and Development Accelerated Access Review
The long-awaited interim report on the Government’s Accelerated Access Review has been published.The Government department overseeing the report, the Office …
New Phase III data puts Shire’s lifitegrast back on track for 2016 launch
October 27, 2015Research and Development Shire, dry eye disease, lifitegrast
Shire shares rose 6% today as the company reported new positive Phase III trial data for lifitegrast in the treatment …
EMA launches scheme to prioritise medicines access for patients
October 27, 2015Manufacturing and Production EMA, European Medicines Agency, medicines access
The EMA has launched a public consultation on a scheme which aims to enable access to more medicines.The PRIME scheme …
North of England secures new ‘centres of excellence’ in ‘precision medicine’
October 27, 2015Manufacturing and Production, Research and Development NHS, Northern Health Science Alliance, UK
The umbrella group formed by the leading northern universities, teaching hospitals and Academic Health Science Networks – the Northern Health …
Roche under pressure to drop price of Kadcyla
October 27, 2015Manufacturing and Production Cancer Drugs Fund, Kadcyla, Roche, breast cancer
The UK’s largest breast cancer charity has called for drug manufacturer Roche to drop the price of Kadcyla before it …
Revealed: recommendations from the Accelerated Access Review
October 27, 2015Manufacturing and Production, Research and Development Accelarated Access Review, NHS
Ministers have been urged to introduce conditional approvals for innovative new drugs, and ‘radically new’ central agreements on drug pricing, …
Novartis misses Q3 forecast with $390m settlement payment, strong dollar
October 27, 2015Manufacturing and Production, Sales and Marketing Alcon, Novartis, Sandoz
Novartis reported lower-than anticipated third quarter earnings on Tuesday, hit by the $390 million settlement it has agreed to pay …
Valeant CEO rejects fraud accusations in conference call
October 27, 2015Manufacturing and Production, Medical Communications, Sales and Marketing
Valeant says it will establish a committee to review allegations about the company’s relationship with specialist pharmacy Philidor, following what …
GSK’s Volibris gets pulmonary arterial hypertension approval in Europe
October 26, 2015Research and Development, Sales and Marketing EMA, GSK
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion …
Imprimis launches low-cost Daraprim alternative
October 26, 2015Sales and Marketing Daraprim, Imprimis, Martin Skhreli, turing
Imprimis Pharmaceuticals has announced that it has made available a customisable compounded formulation of pyrimethamine and leucovorin accessible for physicians …
CEO prepares for day of reckoning over Valeant fraud allegations
October 26, 2015Sales and Marketing J. Michael Pearson, Valeant
Troubled Valeant Pharmaceuticals last week announced strong third quarter revenues, reporting a 36% increase in revenues to $172 million, but …
Puretech Health co-founder and board member Dr Robert Langer wins global engineering prize
October 26, 2015Manufacturing and Production, Research and Development, Sales and Marketing Dr Robert Langer, Engineering, PureTech Health, Queen Elizabeth engineering prize
Dr Robert Langer, the co-founder of PureTech Health, has won the Queen Elizabeth prize for engineering.The award is in recognition …
FDA backs AZ gout drug despite safety concerns
October 26, 2015Sales and Marketing AstraZeneca, Zurampic, gout, lesinurad
FDA reviewers have recommended approving AstraZeneca’s new gout therapy Zurampic, which the company purchased in a $1.3 billion buyout, despite …
Shire reports 7% product sales growth, continues Baxalta pursuit
October 23, 2015Sales and Marketing Baxalta, Shire
Shire has exceeded market expectations as it reported an 11% rise in Q3 earnings on Friday, driven by product sales, …
Novartis’ Cosentyx gets European approval for two conditions
October 23, 2015Medical Communications, Sales and Marketing Cosentyx, European Medicines Agency, Novartis, psoriatic arthritis
The scientific committee of the European Medicines Agency (EMA) has recommended the approval of Novartis’ Cosentyx (secukinumab) for treatment of ankylosing …
Amgen skin cancer drug gets European approval
October 23, 2015Research and Development Amgen, Imlygic, melanoma, skin cancer
Amgen’s Imlygic (talimogene laherparepvec) has been approved by the scientific committee of the European Medicines Agency (EMA) for the treatment of adults …
New general manager for Roche UK
October 23, 2015Medical Communications
Richard Erwin has joined Roche as the new UK General Manager.Richard’s passion for driving sustainable change and championing patient needs …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
